TALZENNA is the first and only PARP inhibitor approved in combination with standard of care XTANDI for mCRPC patients in the European Union
The company has secured two orders for male condoms from CMSS worth Rs. 9.65 crores and Rs. 6.58 crores respectively
Cipla shall now have exclusive rights for the development and commercialisation of Pulmazole in all countries except the United States of America
Lays Foundation Stone of 6 new facilities at AIIMS Bhopal and inaugurates a slew of facilities in Madhya Pradesh
This agreement includes upfront and milestone payments with a combined potential value of over $500m and sales royalties.
The deal includes upfront payments, milestone payments and ongoing royalties
Base4's drug discovery platform allows its collaborators to evaluate billions of novel small molecules to identify and progress RNA-modulators for important diseases
Dapagliflozin and Saxagliptin Tablets (RLD Qtern) had estimated annual sales of US $5 million in the US
Medway setup a state-of-the-art Heart Institute in Chennai
Ribo's cutting edge RIBO-GalSTAR platform enables the development of RNAi therapeutics targeting disease-causing genes specifically in hepatocytes
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
